Sepsis Diagnostics Market Size By Technology (Microbiology, PCR, Immunoassay, microfluidics, Biomarker), Product (Media, Reagent, Instrument), Method (Automated), Test (Lab, POC), Pathogen (Bacterial, Fungal), End User & Region - Global Forecast to 2029
The global sepsis diagnostics market is projected to reach USD 890 million by 2029 from USD 634 million in 2024, growing at a CAGR of 7.0% during the forecast period. The increasing number of sepsis diagnostics procedures is one of the major factors anticipated to boost market growth in the forecasting years. Additionally, the high cost of diagnostic devices affects the growth of the sepsis diagnostics market.
“The blood culture segment to hold the largest share of the market in 2024.”
Based on technology, sepsis diagnostics is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. Blood culture segment is expected to dominate the sepsis diagnostics market during the forecast period. With the increasing sepsis incidences and this technique be the standard technique leading to the growth of this market segment.
“The blood culture media segment to hold the largest share of the market in 2024.”
Based on product, the sepsis diagnostics market is segmented into mesh, sutures, mesh fixator, and other products. The sepsis diagnostics market is expected to be dominated by blood culture media segment during the forecast period. The blood culture media is expected to grow due to their affordable prices as compared to other sepsis diagnostics products.
“The bacterial sepsis segment to hold the largest share of the market in 2024.”
Based on the pathogen type, the sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and other pathogens. The bacterial sepsis segment is further divided into gram-positive bacteria sepsis and gram-negative bacteria sepsis. The bacterial sepsis segment is estimated to hold the largest market share of the sepsis diagnostics market during the forecast period. Rising number of bacterial sepsis cases leads to the increasing growth of the segment in the market.
“The hospitals & speciality clinics segment to hold the largest share of the market in 2024.”
The end user market is segmented into hospitals & speciality clinics, pathology & reference laboratories, and research laboratories, academic institutes & CROs . Hospitals & speciality clinics accounted for the largest share of the global sepsis diagnostics market in 2023 during the forecasted years. This can be attributed to the high patient inflow in this care setting. Only hospitals and clinics can provide the care and monitoring required in exceptionally severe cases, which also accounts for their dominance in the market.
“The market in the North America region is expected to hold a significant market share for sepsis diagnostics in 2022.”
The sepsis diagnostics market covers five key geographies—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for sepsis diagnostics was held by the market in the North American region, comprising the US and Canada. The strong demand for and adoption of sepsis diagnostics in the US led to the growth of the Sepsis diagnostics market in this region.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage
This report studies the sepsis diagnostics market based on technology, product, method, pathogen type, test type, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
“The blood culture segment to hold the largest share of the market in 2024.”
Based on technology, sepsis diagnostics is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. Blood culture segment is expected to dominate the sepsis diagnostics market during the forecast period. With the increasing sepsis incidences and this technique be the standard technique leading to the growth of this market segment.
“The blood culture media segment to hold the largest share of the market in 2024.”
Based on product, the sepsis diagnostics market is segmented into mesh, sutures, mesh fixator, and other products. The sepsis diagnostics market is expected to be dominated by blood culture media segment during the forecast period. The blood culture media is expected to grow due to their affordable prices as compared to other sepsis diagnostics products.
“The bacterial sepsis segment to hold the largest share of the market in 2024.”
Based on the pathogen type, the sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and other pathogens. The bacterial sepsis segment is further divided into gram-positive bacteria sepsis and gram-negative bacteria sepsis. The bacterial sepsis segment is estimated to hold the largest market share of the sepsis diagnostics market during the forecast period. Rising number of bacterial sepsis cases leads to the increasing growth of the segment in the market.
“The hospitals & speciality clinics segment to hold the largest share of the market in 2024.”
The end user market is segmented into hospitals & speciality clinics, pathology & reference laboratories, and research laboratories, academic institutes & CROs . Hospitals & speciality clinics accounted for the largest share of the global sepsis diagnostics market in 2023 during the forecasted years. This can be attributed to the high patient inflow in this care setting. Only hospitals and clinics can provide the care and monitoring required in exceptionally severe cases, which also accounts for their dominance in the market.
“The market in the North America region is expected to hold a significant market share for sepsis diagnostics in 2022.”
The sepsis diagnostics market covers five key geographies—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for sepsis diagnostics was held by the market in the North American region, comprising the US and Canada. The strong demand for and adoption of sepsis diagnostics in the US led to the growth of the Sepsis diagnostics market in this region.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1– 25%, Tier 2– 30%, and Tier 3– 45%
- By Designation: C-level– 26%, Directors– 30%, and Others– 44%
- By Region: North America– 40%, Europe– 31%, Asia Pacific– 20%, Latin America- 6%, MEA- 3%
Research Coverage
This report studies the sepsis diagnostics market based on technology, product, method, pathogen type, test type, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
- Analysis of key drivers (High incidence of sepsis, Rising incidence of hospital-acquired infections (HAIs), Growing funding for sepsis-related research), restraints (High cost of automated diagnostic devices), opportunities (Development of rapid diagnostic/POC techniques for early sepsis diagnosis, Evolution of novel biomarkers for sepsis diagnosis, Growth Opportunities in emerging economies), and challenges (Lack of awareness and limited protocols for sepsis diagnosis, Shortage of skilled healthcare professionals) influencing the growth of the sepsis diagnostics market
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the sepsis diagnostics market
- Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service developments in the sepsis diagnostics market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the sepsis diagnostics market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and services of the leading market players.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIES COVERED
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Indicative list of secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023)
2.2.2 APPROACH 1: PROCEDURE-BASED MARKET ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON PROCEDURE METHODOLOGY
2.2.3 APPROACH 2: END USER-BASED MARKET ESTIMATION
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: SEPSIS DIAGNOSTICS MARKET
2.2.4 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ASSESSMENT
TABLE 1 SEPSIS DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
2.6.1 IMPACT OF RECESSION ON SEPSIS DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 10 SEPSIS DIAGNOSTICS MARKET SHARE, BY METHOD, 2024 VS. 2029
FIGURE 11 SEPSIS DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2024 VS. 2029
FIGURE 12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 13 SEPSIS DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF SEPSIS DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 HIGH INCIDENCE OF SEPSIS TO DRIVE MARKET
4.2 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY (2023)
FIGURE 16 BLOOD CULTURE MEDIA SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
4.3 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 SEPSIS DIAGNOSTICS MARKET: REGIONAL MIX, 2022–2029 (USD MILLION)
FIGURE 18 NORTH AMERICA WILL CONTINUE TO DOMINATE SEPSIS DIAGNOSTICS MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 High incidence of sepsis
5.2.1.2 Rising incidence of HAIs
5.2.1.3 Growing funding for sepsis-related research
5.2.2 RESTRAINTS
5.2.2.1 High cost of automated diagnostic devices
5.2.3 OPPORTUNITIES
5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis
5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis
5.2.3.3 Growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Lack of awareness and limited protocols for sepsis diagnosis
5.2.4.2 Shortage of skilled healthcare professionals
5.3 REGULATORY SCENARIO
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
5.3.2 KEY REGULATORY GUIDELINES
5.3.2.1 North America
5.3.2.1.1 US
5.3.2.1.2 Canada
5.3.2.2 Europe
5.3.2.3 Asia Pacific
5.3.2.3.1 China
5.3.2.3.2 Japan
5.3.2.3.3 India
5.3.2.4 Latin America
5.4 REIMBURSEMENT SCENARIO
TABLE 7 MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS
5.5 VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 PROCUREMENT AND PRODUCT DEVELOPMENT
5.5.3 MARKETING, SALES, AND DISTRIBUTION
FIGURE 20 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 21 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM COVERAGE
FIGURE 22 MARKET MAP
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 INTENSITY OF COMPETITIVE RIVALRY
5.8.2 BARGAINING POWER OF BUYERS
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 THREAT OF NEW ENTRANTS
5.8.5 THREAT OF SUBSTITUTES
5.9 TRADE DATA ANALYSIS
TABLE 9 IMPORT DATA FOR HERNIA MESH (HS CODE 902190), BY COUNTRY, 2018–2022 (USD)
TABLE 10 EXPORT DATA FOR HERNIA MESHES (HS CODE 902190), BY COUNTRY, 2018–2022 (USD)
5.10 PATENT ANALYSIS
FIGURE 23 PATENT ANALYSIS
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND, BY REGION
TABLE 11 SEPSIS DIAGNOSTICS PRICING ANALYSIS, BY REGION, 2023 (USD)
5.11.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
TABLE 12 HERNIA REPAIR PRICING ANALYSIS, BY KEY PLAYER, 2023 (USD)
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 Biomarkers
5.12.1.2 Microfluidics
5.12.2 COMPLIMENTARY TECHNOLOGIES
5.12.2.1 Genomics and Transcriptomics
5.12.2.2 Machine Learning and Artificial Intelligence (AI)
5.12.3 ADJACENT TECHNOLOGIES
5.12.3.1 Nanotechnology Sensors
5.12.3.2 Medical Imaging
5.12.3.3 Digital Health Solutions
5.13 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 13 SEPSIS DIAGNOSTICS: LIST OF MAJOR CONFERENCES & EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
5.15 SEPSIS DIAGNOSTICS MARKET: RECESSION IMPACT
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%)
5.16.2 KEY BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS
TABLE 15 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS
5.17 UNMET NEEDS AND KEY PAIN POINTS
TABLE 16 SEPSIS DIAGNOSTICS MARKET: UNMET CUSTOMER NEEDS AND KEY PAIN POINTS
5.18 INVESTMENT SCENARIO
FIGURE 27 NUMBER OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018–2022
FIGURE 28 VALUE OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)
6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
TABLE 17 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
6.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
6.2.1 MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS
TABLE 18 BLOOD CULTURE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 19 BLOOD CULTURE MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 20 BLOOD CULTURE MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 21 BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 22 BLOOD CULTURE MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 23 BLOOD CULTURE MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 24 BLOOD CULTURE MARKET, BY END USER, 2022–2029 (USD MILLION)
6.3 IMMUNOASSAYS
6.3.1 RISING PRODUCT DEVELOPMENT BY MAJOR PLAYERS TO SUPPORT MARKET GROWTH
TABLE 25 IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 IMMUNOASSAYS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 27 IMMUNOASSAYS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 28 IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 29 IMMUNOASSAYS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 30 IMMUNOASSAYS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 31 IMMUNOASSAYS MARKET, BY END USER, 2022–2029 (USD MILLION)
6.4 MOLECULAR DIAGNOSTICS
TABLE 32 MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 33 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 35 MOLECULAR DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 36 MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 37 MOLECULAR DIAGNOSTICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 38 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 39 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
6.4.1 POLYMERASE CHAIN REACTION
6.4.1.1 Quick turnaround time and technological advancements to propel market
TABLE 40 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.2 MICROARRAYS
6.4.2.1 Simultaneous analysis capabilities & accuracy to boost adoption
TABLE 41 MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION
6.4.3.1 Enables rapid diagnosis of bloodstream infections
TABLE 42 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.4 DNA SEQUENCING
6.4.4.1 Shortens time for sepsis diagnosis
TABLE 43 DNA SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5 FLOW CYTOMETRY
6.5.1 LACK OF STANDARDIZED PROTOCOLS—KEY FACTOR RESTRAINING MARKET GROWTH
TABLE 44 FLOW CYTOMETRY MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 45 FLOW CYTOMETRY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 46 FLOW CYTOMETRY MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 47 FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 48 FLOW CYTOMETRY MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 49 FLOW CYTOMETRY MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 50 FLOW CYTOMETRY MARKET, BY END USER, 2022–2029 (USD MILLION)
6.6 MICROFLUIDICS
6.6.1 RISING ADOPTION OF ADVANCED AND RAPID TESTING TO DRIVE GROWTH
TABLE 51 MICROFLUIDICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 52 MICROFLUIDICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 53 MICROFLUIDICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 54 MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 55 MICROFLUIDICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 56 MICROFLUIDICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 57 MICROFLUIDICS MARKET, BY END USER, 2022–2029 (USD MILLION)
6.7 BIOMARKERS
6.7.1 RESEARCH & DEVELOPMENT FOR DISCOVERY OF NOVEL BIOMARKERS TO DRIVE GROWTH
TABLE 58 BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 59 BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 60 BIOMARKERS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 61 BIOMARKERS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 62 BIOMARKERS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 63 BIOMARKERS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 64 BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT
7.1 INTRODUCTION
TABLE 65 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
7.2 BLOOD CULTURE MEDIA
7.2.1 RISE IN BLOODSTREAM INFECTIONS TO DRIVE GROWTH
TABLE 66 SEPSIS DIAGNOSTIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2022–2029 (USD MILLION)
7.3 ASSAYS & REAGENT KITS
7.3.1 ASSAYS BETTER ENABLE ANALYSIS OF PATIENT SAMPLES FOR DISEASE DIAGNOSIS
TABLE 67 SEPSIS DIAGNOSTIC ASSAYS & REAGENT KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
7.4 INSTRUMENTS
7.4.1 INCREASING INCLINATION TOWARD RAPID DIAGNOSTIC SYSTEMS TO DRIVE MARKET
TABLE 68 SEPSIS DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
7.5 SOFTWARE
7.5.1 INCREASING USE OF AUTOMATED INSTRUMENTS TO DRIVE DEMAND FOR SOFTWARE
TABLE 69 SEPSIS DIAGNOSTIC SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
8 SEPSIS DIAGNOSTICS MARKET, BY METHOD
8.1 INTRODUCTION
TABLE 70 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
8.2 CONVENTIONAL DIAGNOSTICS
8.2.1 EASE OF USE AND LOW COST TO PROPEL MARKET GROWTH
TABLE 71 CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3 AUTOMATED DIAGNOSTICS
8.3.1 ACCURACY AND QUICK TURNAROUND TIME TO DRIVE ADOPTION
TABLE 72 AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE
9.1 INTRODUCTION
TABLE 73 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
9.2 BACTERIAL SEPSIS
TABLE 74 BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 75 BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
9.2.1.1 Increasing demand for sepsis diagnostic tests to drive market
TABLE 76 GRAM-NEGATIVE BACTERIAL CAUSES IN ADULTS
TABLE 77 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
9.2.2.1 Increasing incidence of gram-positive nosocomial infections to propel market
TABLE 78 GRAM-POSITIVE BACTERIAL CAUSES IN ADULTS
TABLE 79 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
9.3 FUNGAL SEPSIS
9.3.1 RISING INCIDENCE OF FUNGAL INFECTIONS TO PROPEL MARKET
TABLE 80 FUNGAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
9.4 OTHER PATHOGEN TYPES
TABLE 81 OTHER PATHOGEN TYPES MARKET, BY REGION, 2022–2029 (USD MILLION)
10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE
10.1 INTRODUCTION
TABLE 82 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
10.2 LABORATORY TESTS
10.2.1 MOST COMMON AND PREFERRED MODE OF TESTING
TABLE 83 LABORATORY SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
10.3 POINT-OF-CARE TESTS
10.3.1 INCREASING DEVELOPMENT OF NOVEL POC DIAGNOSTICS TO SUPPORT MARKET GROWTH
TABLE 84 POINT-OF-CARE SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
11 SEPSIS DIAGNOSTICS MARKET, BY END USER
11.1 INTRODUCTION
TABLE 85 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2 HOSPITALS AND SPECIALTY CLINICS
11.2.1 INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO DRIVE MARKET
TABLE 86 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY REGION, 2022–2029 (USD MILLION)
11.3 PATHOLOGY AND REFERENCE LABORATORIES
11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES
TABLE 87 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY AND REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
11.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS
11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION TO DRIVE GROWTH
TABLE 88 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2022–2029 (USD MILLION)
12 SEPSIS DIAGNOSTICS MARKET, BY REGION
12.1 INTRODUCTION
TABLE 89 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
TABLE 90 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 92 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 93 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 98 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.3 RECESSION IMPACT ON NORTH AMERICAN SEPSIS DIAGNOSTICS MARKET
12.3.1 US
12.3.1.1 Rising incidence of HAIs to drive demand
TABLE 99 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 100 US: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.3.2 CANADA
12.3.2.1 Growing availability of sepsis diagnostic products to support market growth
TABLE 101 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 102 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4 EUROPE
TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 105 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 106 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 108 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 109 EUROPE: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 110 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 111 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.4.1 RECESSION IMPACT ON EUROPEAN SEPSIS DIAGNOSTICS MARKET
12.4.2 GERMANY
12.4.2.1 Adoption of technologically advanced diagnostic products to drive market
TABLE 112 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 113 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.3 UK
12.4.3.1 Stringent government regulations to drive market growth
TABLE 114 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 115 UK: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.4 FRANCE
12.4.4.1 High incidence of sepsis to propel growth
TABLE 116 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 117 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.5 ITALY
12.4.5.1 Supportive government initiatives for raising awareness on sepsis to drive market
TABLE 118 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.6 SPAIN
12.4.6.1 Rising awareness for early diagnosis of propel market
TABLE 120 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.7 REST OF EUROPE
TABLE 122 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 123 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
TABLE 124 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 126 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 127 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 128 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 129 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 130 ASIA PACIFIC: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 132 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.5.1 RECESSION IMPACT ON ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET
12.5.2 JAPAN
12.5.2.1 Rising incidence of pneumonia and infectious diseases to support market growth
TABLE 133 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 134 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.3 CHINA
12.5.3.1 Healthcare infrastructure improvements to support market growth
TABLE 135 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 136 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.4 INDIA
12.5.4.1 Increasing patient population and rising number of surgical procedures to drive market
TABLE 137 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 138 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.5 AUSTRALIA
12.5.5.1 Rapid growth in sepsis treatment procedures to propel market
TABLE 139 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 140 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.6 SOUTH KOREA
12.5.6.1 Rising healthcare spending to support market growth
TABLE 141 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 142 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.7 REST OF ASIA PACIFIC
TABLE 143 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.6 LATIN AMERICA
TABLE 145 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 146 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 147 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 148 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 149 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 150 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 151 LATIN AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 152 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 153 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.6.1 RECESSION IMPACT ON LATIN AMERICAN SEPSIS DIAGNOSTICS MARKET
12.6.2 BRAZIL
12.6.2.1 Investments by leading sepsis diagnostic manufacturers to support market growth
TABLE 154 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 155 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.6.3 MEXICO
12.6.3.1 Rising medical tourism to drive market
TABLE 156 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 157 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.6.4 REST OF LATIN AMERICA
TABLE 158 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 159 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.7 MIDDLE EAST & AFRICA
12.7.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS TO PROPEL MARKET
TABLE 160 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 161 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 164 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 165 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 166 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 167 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 168 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.7.2 RECESSION IMPACT ON MIDDLE EAST & AFRICAN SEPSIS DIAGNOSTICS MARKET
12.7.3 GCC COUNTRIES
12.7.3.1 Developments in healthcare infrastructure to drive market
TABLE 169 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 170 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.7.4 REST OF MIDDLE EAST & AFRICA
TABLE 171 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 172 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 31 SEPSIS DIAGNOSTICS MARKET: STRATEGIES ADOPTED
13.3 REVENUE SHARE ANALYSIS
FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020–2022 (USD MILLION)
13.4 MARKET SHARE ANALYSIS
13.4.1 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 33 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 173 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION
13.4.2 BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 34 BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023
13.4.3 IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 35 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2023
13.4.4 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 36 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
13.4.5 BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 37 BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 38 SEPSIS DIAGNOSTICS MARKET RANKING (2023)
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
FIGURE 39 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
13.5.5 COMPETITIVE FOOTPRINT
13.5.5.1 Overall company footprint
FIGURE 40 SEPSIS DIAGNOSTICS MARKET: OVERALL COMPANY FOOTPRINT
13.5.5.2 Regional footprint
TABLE 174 SEPSIS DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
13.5.5.3 Technology footprint
TABLE 175 SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
13.5.5.4 Product footprint
TABLE 176 SEPSIS DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
13.5.5.5 Pathogen type footprint
TABLE 177 SEPSIS DIAGNOSTICS MARKET: PATHOGEN TYPE FOOTPRINT
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
FIGURE 41 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
13.6.5 COMPETITIVE BENCHMARKING
TABLE 178 SEPSIS DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 179 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
13.7 VALUATION AND FINANCIAL METRICS OF SEPSIS DIAGNOSTIC VENDORS
FIGURE 42 EV/EBITDA OF KEY VENDORS
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
13.8 PRODUCT/BRAND COMPARATIVE ANALYSIS
FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL (2023)
13.8.1 BIOMЙRIEUX
13.8.2 BECTON, DICKINSON AND COMPANY
13.8.3 F. HOFFMANN-LA ROCHE LTD.
13.8.4 DANAHER CORPORATION
13.8.5 QIAGEN N.V.
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 180 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MARCH 2024
13.9.2 DEALS
TABLE 181 SEPSIS DIAGNOSTICS MARKET: DEALS, JANUARY 2019–MARCH 2024
13.9.3 EXPANSIONS
TABLE 182 SEPSIS DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2019–MARCH 2024
14 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
14.1 KEY PLAYERS
14.1.1 BIOMЙRIEUX
TABLE 183 BIOMЙRIEUX: COMPANY OVERVIEW
FIGURE 45 BIOMЙRIEUX: COMPANY SNAPSHOT (2022)
TABLE 184 BIOMЙRIEUX: PRODUCTS OFFERED
TABLE 185 BIOMЙRIEUX: PRODUCT LAUNCHES & APPROVALS
TABLE 186 BIOMЙRIEUX: DEALS
TABLE 187 BIOMЙRIEUX: OTHER DEVELOPMENTS
14.1.2 BECTON, DICKINSON AND COMPANY
TABLE 188 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 189 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
TABLE 190 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS
TABLE 191 BECTON, DICKINSON AND COMPANY: EXPANSIONS
14.1.3 DANAHER CORPORATION
TABLE 192 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 47 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 193 DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 194 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 195 DANAHER CORPORATION: DEALS
14.1.4 T2 BIOSYSTEMS, INC.
TABLE 196 T2 BIOSYSTEMS INC.: COMPANY OVERVIEW
FIGURE 48 T2 BIOSYSTEMS INC.: COMPANY SNAPSHOT (2022)
TABLE 197 T2 BIOSYSTEMS, INC.: PRODUCTS OFFERED
TABLE 198 T2 BIOSYSTEMS, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 199 T2 BIOSYSTEMS, INC.: DEALS
TABLE 200 T2 BIOSYSTEMS, INC.: EXPANSIONS
14.1.5 DIASORIN S.P.A.
TABLE 201 DIASORIN S.P.A.: COMPANY OVERVIEW
FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
TABLE 202 DIASORIN S.P.A.: PRODUCTS OFFERED
TABLE 203 DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS
TABLE 204 DIASORIN S.P.A.: DEALS
14.1.6 F. HOFFMANN-LA ROCHE LTD.
TABLE 205 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
TABLE 206 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 207 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
TABLE 208 F. HOFFMANN-LA ROCHE LTD.: DEALS
14.1.7 THERMO FISHER SCIENTIFIC INC.
TABLE 209 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 210 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 211 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 212 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
TABLE 213 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS
14.1.8 BRUKER CORPORATION
TABLE 214 BRUKER CORPORATION: COMPANY OVERVIEW
FIGURE 52 BRUKER CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 215 BRUKER CORPORATION: PRODUCTS OFFERED
TABLE 216 BRUKER CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 217 BRUKER CORPORATION: DEALS
14.1.9 QUIDELORTHO CORPORATION
TABLE 218 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
FIGURE 53 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 219 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
14.1.10 SYSMEX CORPORATION
TABLE 220 SYSMEX CORPORATION: COMPANY OVERVIEW
FIGURE 54 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 221 SYSMEX CORPORATION: PRODUCTS OFFERED
TABLE 222 SYSMEX CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 223 SYSMEX CORPORATION: OTHER DEVELOPMENTS
14.1.11 ABBOTT LABORATORIES
TABLE 224 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 55 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
TABLE 225 ABBOTT LABORATORIES: PRODUCTS OFFERED
14.1.12 SIEMENS HEALTHINEERS
TABLE 226 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
FIGURE 56 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023)
TABLE 227 SIEMENS HEALTHINEERS: PRODUCTS OFFERED
TABLE 228 SIEMENS HEALTHINEERS: PRODUCT APPROVALS
TABLE 229 SIEMENS HEALTHINEERS: DEALS
TABLE 230 SIEMENS HEALTHINEERS: EXPANSIONS
14.1.13 QIAGEN N.V.
TABLE 231 QIAGEN N.V.: COMPANY OVERVIEW
FIGURE 57 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
TABLE 232 QIAGEN N.V.: PRODUCTS OFFERED
TABLE 233 QIAGEN N.V.: DEALS
TABLE 234 QIAGEN N.V.: EXPANSIONS
14.1.14 SEEGENE, INC.
TABLE 235 SEEGENE, INC.: COMPANY OVERVIEW
TABLE 236 SEEGENE, INC.: PRODUCTS OFFERED
14.1.15 PHC HOLDINGS CORPORATION
TABLE 237 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 238 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED
TABLE 239 PHC HOLDINGS CORPORATION: DEALS
14.2 OTHER PLAYERS
14.2.1 MCKESSON CORPORATION
TABLE 240 MCKESSON CORPORATION: COMPANY OVERVIEW
14.2.2 EKF DIAGNOSTICS HOLDINGS PLC
TABLE 241 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
14.2.3 RESPONSE BIOMEDICAL CORP.
TABLE 242 RESPONSE BIOMEDICAL CORP.: COMPANY OVERVIEW
14.2.4 ALIFAX S.R.L.
TABLE 243 ALIFAX S.R.L.: COMPANY OVERVIEW
14.2.5 BODITECH MED INC.
TABLE 244 BODITECH MED INC.: COMPANY OVERVIEW
14.2.6 ADVANDX
TABLE 245 ADVANDX: COMPANY OVERVIEW
14.2.7 IMMUNEXPRESS INC.
TABLE 246 IMMUNEXPRESS INC.: COMPANY OVERVIEW
14.2.8 AXIS-SHIELD DIAGNOSTICS
TABLE 247 AXIS-SHIELD DIAGNOSTICS: COMPANY OVERVIEW
14.2.9 FUJIREBIO
TABLE 248 FUJIREBIO: COMPANY OVERVIEW
14.2.10 SEKISUI DIAGNOSTICS
TABLE 249 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
14.2.11 CURETIS GMBH
TABLE 250 CURETIS GMBH: COMPANY OVERVIEW
14.2.12 NAN?MIX INC.
TABLE 251 NAN?MIX INC.: COMPANY OVERVIEW
14.2.13 QVELLA CORPORATION
TABLE 252 QVELLA CORPORATION: COMPANY OVERVIEW
14.2.14 MOLZYM GMBH & CO. KG
TABLE 253 MOLZYM GMBH & CO. KG: COMPANY OVERVIEW
14.2.15 CYTOVALE, INC.
TABLE 254 CYTOVALE, INC.: COMPANY OVERVIEW
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIES COVERED
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Indicative list of secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023)
2.2.2 APPROACH 1: PROCEDURE-BASED MARKET ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON PROCEDURE METHODOLOGY
2.2.3 APPROACH 2: END USER-BASED MARKET ESTIMATION
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: SEPSIS DIAGNOSTICS MARKET
2.2.4 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ASSESSMENT
TABLE 1 SEPSIS DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
2.6.1 IMPACT OF RECESSION ON SEPSIS DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 10 SEPSIS DIAGNOSTICS MARKET SHARE, BY METHOD, 2024 VS. 2029
FIGURE 11 SEPSIS DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2024 VS. 2029
FIGURE 12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 13 SEPSIS DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF SEPSIS DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 HIGH INCIDENCE OF SEPSIS TO DRIVE MARKET
4.2 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY (2023)
FIGURE 16 BLOOD CULTURE MEDIA SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
4.3 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 SEPSIS DIAGNOSTICS MARKET: REGIONAL MIX, 2022–2029 (USD MILLION)
FIGURE 18 NORTH AMERICA WILL CONTINUE TO DOMINATE SEPSIS DIAGNOSTICS MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 High incidence of sepsis
5.2.1.2 Rising incidence of HAIs
5.2.1.3 Growing funding for sepsis-related research
5.2.2 RESTRAINTS
5.2.2.1 High cost of automated diagnostic devices
5.2.3 OPPORTUNITIES
5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis
5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis
5.2.3.3 Growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Lack of awareness and limited protocols for sepsis diagnosis
5.2.4.2 Shortage of skilled healthcare professionals
5.3 REGULATORY SCENARIO
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
5.3.2 KEY REGULATORY GUIDELINES
5.3.2.1 North America
5.3.2.1.1 US
5.3.2.1.2 Canada
5.3.2.2 Europe
5.3.2.3 Asia Pacific
5.3.2.3.1 China
5.3.2.3.2 Japan
5.3.2.3.3 India
5.3.2.4 Latin America
5.4 REIMBURSEMENT SCENARIO
TABLE 7 MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS
5.5 VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 PROCUREMENT AND PRODUCT DEVELOPMENT
5.5.3 MARKETING, SALES, AND DISTRIBUTION
FIGURE 20 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 21 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM COVERAGE
FIGURE 22 MARKET MAP
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 INTENSITY OF COMPETITIVE RIVALRY
5.8.2 BARGAINING POWER OF BUYERS
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 THREAT OF NEW ENTRANTS
5.8.5 THREAT OF SUBSTITUTES
5.9 TRADE DATA ANALYSIS
TABLE 9 IMPORT DATA FOR HERNIA MESH (HS CODE 902190), BY COUNTRY, 2018–2022 (USD)
TABLE 10 EXPORT DATA FOR HERNIA MESHES (HS CODE 902190), BY COUNTRY, 2018–2022 (USD)
5.10 PATENT ANALYSIS
FIGURE 23 PATENT ANALYSIS
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND, BY REGION
TABLE 11 SEPSIS DIAGNOSTICS PRICING ANALYSIS, BY REGION, 2023 (USD)
5.11.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
TABLE 12 HERNIA REPAIR PRICING ANALYSIS, BY KEY PLAYER, 2023 (USD)
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 Biomarkers
5.12.1.2 Microfluidics
5.12.2 COMPLIMENTARY TECHNOLOGIES
5.12.2.1 Genomics and Transcriptomics
5.12.2.2 Machine Learning and Artificial Intelligence (AI)
5.12.3 ADJACENT TECHNOLOGIES
5.12.3.1 Nanotechnology Sensors
5.12.3.2 Medical Imaging
5.12.3.3 Digital Health Solutions
5.13 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 13 SEPSIS DIAGNOSTICS: LIST OF MAJOR CONFERENCES & EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
5.15 SEPSIS DIAGNOSTICS MARKET: RECESSION IMPACT
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%)
5.16.2 KEY BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS
TABLE 15 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS
5.17 UNMET NEEDS AND KEY PAIN POINTS
TABLE 16 SEPSIS DIAGNOSTICS MARKET: UNMET CUSTOMER NEEDS AND KEY PAIN POINTS
5.18 INVESTMENT SCENARIO
FIGURE 27 NUMBER OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018–2022
FIGURE 28 VALUE OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)
6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
TABLE 17 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
6.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
6.2.1 MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS
TABLE 18 BLOOD CULTURE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 19 BLOOD CULTURE MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 20 BLOOD CULTURE MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 21 BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 22 BLOOD CULTURE MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 23 BLOOD CULTURE MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 24 BLOOD CULTURE MARKET, BY END USER, 2022–2029 (USD MILLION)
6.3 IMMUNOASSAYS
6.3.1 RISING PRODUCT DEVELOPMENT BY MAJOR PLAYERS TO SUPPORT MARKET GROWTH
TABLE 25 IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 IMMUNOASSAYS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 27 IMMUNOASSAYS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 28 IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 29 IMMUNOASSAYS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 30 IMMUNOASSAYS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 31 IMMUNOASSAYS MARKET, BY END USER, 2022–2029 (USD MILLION)
6.4 MOLECULAR DIAGNOSTICS
TABLE 32 MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 33 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 35 MOLECULAR DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 36 MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 37 MOLECULAR DIAGNOSTICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 38 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 39 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
6.4.1 POLYMERASE CHAIN REACTION
6.4.1.1 Quick turnaround time and technological advancements to propel market
TABLE 40 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.2 MICROARRAYS
6.4.2.1 Simultaneous analysis capabilities & accuracy to boost adoption
TABLE 41 MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION
6.4.3.1 Enables rapid diagnosis of bloodstream infections
TABLE 42 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.4 DNA SEQUENCING
6.4.4.1 Shortens time for sepsis diagnosis
TABLE 43 DNA SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5 FLOW CYTOMETRY
6.5.1 LACK OF STANDARDIZED PROTOCOLS—KEY FACTOR RESTRAINING MARKET GROWTH
TABLE 44 FLOW CYTOMETRY MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 45 FLOW CYTOMETRY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 46 FLOW CYTOMETRY MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 47 FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 48 FLOW CYTOMETRY MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 49 FLOW CYTOMETRY MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 50 FLOW CYTOMETRY MARKET, BY END USER, 2022–2029 (USD MILLION)
6.6 MICROFLUIDICS
6.6.1 RISING ADOPTION OF ADVANCED AND RAPID TESTING TO DRIVE GROWTH
TABLE 51 MICROFLUIDICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 52 MICROFLUIDICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 53 MICROFLUIDICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 54 MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 55 MICROFLUIDICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 56 MICROFLUIDICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 57 MICROFLUIDICS MARKET, BY END USER, 2022–2029 (USD MILLION)
6.7 BIOMARKERS
6.7.1 RESEARCH & DEVELOPMENT FOR DISCOVERY OF NOVEL BIOMARKERS TO DRIVE GROWTH
TABLE 58 BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 59 BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 60 BIOMARKERS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 61 BIOMARKERS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 62 BIOMARKERS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 63 BIOMARKERS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 64 BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT
7.1 INTRODUCTION
TABLE 65 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
7.2 BLOOD CULTURE MEDIA
7.2.1 RISE IN BLOODSTREAM INFECTIONS TO DRIVE GROWTH
TABLE 66 SEPSIS DIAGNOSTIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2022–2029 (USD MILLION)
7.3 ASSAYS & REAGENT KITS
7.3.1 ASSAYS BETTER ENABLE ANALYSIS OF PATIENT SAMPLES FOR DISEASE DIAGNOSIS
TABLE 67 SEPSIS DIAGNOSTIC ASSAYS & REAGENT KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
7.4 INSTRUMENTS
7.4.1 INCREASING INCLINATION TOWARD RAPID DIAGNOSTIC SYSTEMS TO DRIVE MARKET
TABLE 68 SEPSIS DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
7.5 SOFTWARE
7.5.1 INCREASING USE OF AUTOMATED INSTRUMENTS TO DRIVE DEMAND FOR SOFTWARE
TABLE 69 SEPSIS DIAGNOSTIC SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
8 SEPSIS DIAGNOSTICS MARKET, BY METHOD
8.1 INTRODUCTION
TABLE 70 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
8.2 CONVENTIONAL DIAGNOSTICS
8.2.1 EASE OF USE AND LOW COST TO PROPEL MARKET GROWTH
TABLE 71 CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3 AUTOMATED DIAGNOSTICS
8.3.1 ACCURACY AND QUICK TURNAROUND TIME TO DRIVE ADOPTION
TABLE 72 AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE
9.1 INTRODUCTION
TABLE 73 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
9.2 BACTERIAL SEPSIS
TABLE 74 BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 75 BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
9.2.1.1 Increasing demand for sepsis diagnostic tests to drive market
TABLE 76 GRAM-NEGATIVE BACTERIAL CAUSES IN ADULTS
TABLE 77 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
9.2.2.1 Increasing incidence of gram-positive nosocomial infections to propel market
TABLE 78 GRAM-POSITIVE BACTERIAL CAUSES IN ADULTS
TABLE 79 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
9.3 FUNGAL SEPSIS
9.3.1 RISING INCIDENCE OF FUNGAL INFECTIONS TO PROPEL MARKET
TABLE 80 FUNGAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
9.4 OTHER PATHOGEN TYPES
TABLE 81 OTHER PATHOGEN TYPES MARKET, BY REGION, 2022–2029 (USD MILLION)
10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE
10.1 INTRODUCTION
TABLE 82 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
10.2 LABORATORY TESTS
10.2.1 MOST COMMON AND PREFERRED MODE OF TESTING
TABLE 83 LABORATORY SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
10.3 POINT-OF-CARE TESTS
10.3.1 INCREASING DEVELOPMENT OF NOVEL POC DIAGNOSTICS TO SUPPORT MARKET GROWTH
TABLE 84 POINT-OF-CARE SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
11 SEPSIS DIAGNOSTICS MARKET, BY END USER
11.1 INTRODUCTION
TABLE 85 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2 HOSPITALS AND SPECIALTY CLINICS
11.2.1 INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO DRIVE MARKET
TABLE 86 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY REGION, 2022–2029 (USD MILLION)
11.3 PATHOLOGY AND REFERENCE LABORATORIES
11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES
TABLE 87 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY AND REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
11.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS
11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION TO DRIVE GROWTH
TABLE 88 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2022–2029 (USD MILLION)
12 SEPSIS DIAGNOSTICS MARKET, BY REGION
12.1 INTRODUCTION
TABLE 89 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
TABLE 90 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 92 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 93 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 98 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.3 RECESSION IMPACT ON NORTH AMERICAN SEPSIS DIAGNOSTICS MARKET
12.3.1 US
12.3.1.1 Rising incidence of HAIs to drive demand
TABLE 99 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 100 US: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.3.2 CANADA
12.3.2.1 Growing availability of sepsis diagnostic products to support market growth
TABLE 101 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 102 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4 EUROPE
TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 105 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 106 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 108 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 109 EUROPE: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 110 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 111 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.4.1 RECESSION IMPACT ON EUROPEAN SEPSIS DIAGNOSTICS MARKET
12.4.2 GERMANY
12.4.2.1 Adoption of technologically advanced diagnostic products to drive market
TABLE 112 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 113 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.3 UK
12.4.3.1 Stringent government regulations to drive market growth
TABLE 114 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 115 UK: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.4 FRANCE
12.4.4.1 High incidence of sepsis to propel growth
TABLE 116 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 117 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.5 ITALY
12.4.5.1 Supportive government initiatives for raising awareness on sepsis to drive market
TABLE 118 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.6 SPAIN
12.4.6.1 Rising awareness for early diagnosis of propel market
TABLE 120 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.4.7 REST OF EUROPE
TABLE 122 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 123 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
TABLE 124 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 126 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 127 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 128 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 129 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 130 ASIA PACIFIC: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 132 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.5.1 RECESSION IMPACT ON ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET
12.5.2 JAPAN
12.5.2.1 Rising incidence of pneumonia and infectious diseases to support market growth
TABLE 133 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 134 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.3 CHINA
12.5.3.1 Healthcare infrastructure improvements to support market growth
TABLE 135 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 136 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.4 INDIA
12.5.4.1 Increasing patient population and rising number of surgical procedures to drive market
TABLE 137 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 138 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.5 AUSTRALIA
12.5.5.1 Rapid growth in sepsis treatment procedures to propel market
TABLE 139 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 140 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.6 SOUTH KOREA
12.5.6.1 Rising healthcare spending to support market growth
TABLE 141 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 142 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.5.7 REST OF ASIA PACIFIC
TABLE 143 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.6 LATIN AMERICA
TABLE 145 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 146 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 147 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 148 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 149 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 150 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 151 LATIN AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 152 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 153 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.6.1 RECESSION IMPACT ON LATIN AMERICAN SEPSIS DIAGNOSTICS MARKET
12.6.2 BRAZIL
12.6.2.1 Investments by leading sepsis diagnostic manufacturers to support market growth
TABLE 154 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 155 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.6.3 MEXICO
12.6.3.1 Rising medical tourism to drive market
TABLE 156 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 157 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.6.4 REST OF LATIN AMERICA
TABLE 158 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 159 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.7 MIDDLE EAST & AFRICA
12.7.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS TO PROPEL MARKET
TABLE 160 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 161 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 164 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
TABLE 165 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
TABLE 166 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 167 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
TABLE 168 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
12.7.2 RECESSION IMPACT ON MIDDLE EAST & AFRICAN SEPSIS DIAGNOSTICS MARKET
12.7.3 GCC COUNTRIES
12.7.3.1 Developments in healthcare infrastructure to drive market
TABLE 169 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 170 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
12.7.4 REST OF MIDDLE EAST & AFRICA
TABLE 171 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 172 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 31 SEPSIS DIAGNOSTICS MARKET: STRATEGIES ADOPTED
13.3 REVENUE SHARE ANALYSIS
FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020–2022 (USD MILLION)
13.4 MARKET SHARE ANALYSIS
13.4.1 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 33 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 173 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION
13.4.2 BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 34 BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023
13.4.3 IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 35 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2023
13.4.4 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 36 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
13.4.5 BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 37 BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 38 SEPSIS DIAGNOSTICS MARKET RANKING (2023)
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
FIGURE 39 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
13.5.5 COMPETITIVE FOOTPRINT
13.5.5.1 Overall company footprint
FIGURE 40 SEPSIS DIAGNOSTICS MARKET: OVERALL COMPANY FOOTPRINT
13.5.5.2 Regional footprint
TABLE 174 SEPSIS DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
13.5.5.3 Technology footprint
TABLE 175 SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
13.5.5.4 Product footprint
TABLE 176 SEPSIS DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
13.5.5.5 Pathogen type footprint
TABLE 177 SEPSIS DIAGNOSTICS MARKET: PATHOGEN TYPE FOOTPRINT
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
FIGURE 41 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
13.6.5 COMPETITIVE BENCHMARKING
TABLE 178 SEPSIS DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 179 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
13.7 VALUATION AND FINANCIAL METRICS OF SEPSIS DIAGNOSTIC VENDORS
FIGURE 42 EV/EBITDA OF KEY VENDORS
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
13.8 PRODUCT/BRAND COMPARATIVE ANALYSIS
FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL (2023)
13.8.1 BIOMЙRIEUX
13.8.2 BECTON, DICKINSON AND COMPANY
13.8.3 F. HOFFMANN-LA ROCHE LTD.
13.8.4 DANAHER CORPORATION
13.8.5 QIAGEN N.V.
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 180 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MARCH 2024
13.9.2 DEALS
TABLE 181 SEPSIS DIAGNOSTICS MARKET: DEALS, JANUARY 2019–MARCH 2024
13.9.3 EXPANSIONS
TABLE 182 SEPSIS DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2019–MARCH 2024
14 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
14.1 KEY PLAYERS
14.1.1 BIOMЙRIEUX
TABLE 183 BIOMЙRIEUX: COMPANY OVERVIEW
FIGURE 45 BIOMЙRIEUX: COMPANY SNAPSHOT (2022)
TABLE 184 BIOMЙRIEUX: PRODUCTS OFFERED
TABLE 185 BIOMЙRIEUX: PRODUCT LAUNCHES & APPROVALS
TABLE 186 BIOMЙRIEUX: DEALS
TABLE 187 BIOMЙRIEUX: OTHER DEVELOPMENTS
14.1.2 BECTON, DICKINSON AND COMPANY
TABLE 188 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 189 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
TABLE 190 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS
TABLE 191 BECTON, DICKINSON AND COMPANY: EXPANSIONS
14.1.3 DANAHER CORPORATION
TABLE 192 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 47 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 193 DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 194 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 195 DANAHER CORPORATION: DEALS
14.1.4 T2 BIOSYSTEMS, INC.
TABLE 196 T2 BIOSYSTEMS INC.: COMPANY OVERVIEW
FIGURE 48 T2 BIOSYSTEMS INC.: COMPANY SNAPSHOT (2022)
TABLE 197 T2 BIOSYSTEMS, INC.: PRODUCTS OFFERED
TABLE 198 T2 BIOSYSTEMS, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 199 T2 BIOSYSTEMS, INC.: DEALS
TABLE 200 T2 BIOSYSTEMS, INC.: EXPANSIONS
14.1.5 DIASORIN S.P.A.
TABLE 201 DIASORIN S.P.A.: COMPANY OVERVIEW
FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
TABLE 202 DIASORIN S.P.A.: PRODUCTS OFFERED
TABLE 203 DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS
TABLE 204 DIASORIN S.P.A.: DEALS
14.1.6 F. HOFFMANN-LA ROCHE LTD.
TABLE 205 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
TABLE 206 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 207 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
TABLE 208 F. HOFFMANN-LA ROCHE LTD.: DEALS
14.1.7 THERMO FISHER SCIENTIFIC INC.
TABLE 209 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 210 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 211 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 212 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
TABLE 213 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS
14.1.8 BRUKER CORPORATION
TABLE 214 BRUKER CORPORATION: COMPANY OVERVIEW
FIGURE 52 BRUKER CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 215 BRUKER CORPORATION: PRODUCTS OFFERED
TABLE 216 BRUKER CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 217 BRUKER CORPORATION: DEALS
14.1.9 QUIDELORTHO CORPORATION
TABLE 218 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
FIGURE 53 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 219 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
14.1.10 SYSMEX CORPORATION
TABLE 220 SYSMEX CORPORATION: COMPANY OVERVIEW
FIGURE 54 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 221 SYSMEX CORPORATION: PRODUCTS OFFERED
TABLE 222 SYSMEX CORPORATION: PRODUCT LAUNCHES & APPROVALS
TABLE 223 SYSMEX CORPORATION: OTHER DEVELOPMENTS
14.1.11 ABBOTT LABORATORIES
TABLE 224 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 55 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
TABLE 225 ABBOTT LABORATORIES: PRODUCTS OFFERED
14.1.12 SIEMENS HEALTHINEERS
TABLE 226 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
FIGURE 56 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023)
TABLE 227 SIEMENS HEALTHINEERS: PRODUCTS OFFERED
TABLE 228 SIEMENS HEALTHINEERS: PRODUCT APPROVALS
TABLE 229 SIEMENS HEALTHINEERS: DEALS
TABLE 230 SIEMENS HEALTHINEERS: EXPANSIONS
14.1.13 QIAGEN N.V.
TABLE 231 QIAGEN N.V.: COMPANY OVERVIEW
FIGURE 57 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
TABLE 232 QIAGEN N.V.: PRODUCTS OFFERED
TABLE 233 QIAGEN N.V.: DEALS
TABLE 234 QIAGEN N.V.: EXPANSIONS
14.1.14 SEEGENE, INC.
TABLE 235 SEEGENE, INC.: COMPANY OVERVIEW
TABLE 236 SEEGENE, INC.: PRODUCTS OFFERED
14.1.15 PHC HOLDINGS CORPORATION
TABLE 237 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 238 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED
TABLE 239 PHC HOLDINGS CORPORATION: DEALS
14.2 OTHER PLAYERS
14.2.1 MCKESSON CORPORATION
TABLE 240 MCKESSON CORPORATION: COMPANY OVERVIEW
14.2.2 EKF DIAGNOSTICS HOLDINGS PLC
TABLE 241 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
14.2.3 RESPONSE BIOMEDICAL CORP.
TABLE 242 RESPONSE BIOMEDICAL CORP.: COMPANY OVERVIEW
14.2.4 ALIFAX S.R.L.
TABLE 243 ALIFAX S.R.L.: COMPANY OVERVIEW
14.2.5 BODITECH MED INC.
TABLE 244 BODITECH MED INC.: COMPANY OVERVIEW
14.2.6 ADVANDX
TABLE 245 ADVANDX: COMPANY OVERVIEW
14.2.7 IMMUNEXPRESS INC.
TABLE 246 IMMUNEXPRESS INC.: COMPANY OVERVIEW
14.2.8 AXIS-SHIELD DIAGNOSTICS
TABLE 247 AXIS-SHIELD DIAGNOSTICS: COMPANY OVERVIEW
14.2.9 FUJIREBIO
TABLE 248 FUJIREBIO: COMPANY OVERVIEW
14.2.10 SEKISUI DIAGNOSTICS
TABLE 249 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
14.2.11 CURETIS GMBH
TABLE 250 CURETIS GMBH: COMPANY OVERVIEW
14.2.12 NAN?MIX INC.
TABLE 251 NAN?MIX INC.: COMPANY OVERVIEW
14.2.13 QVELLA CORPORATION
TABLE 252 QVELLA CORPORATION: COMPANY OVERVIEW
14.2.14 MOLZYM GMBH & CO. KG
TABLE 253 MOLZYM GMBH & CO. KG: COMPANY OVERVIEW
14.2.15 CYTOVALE, INC.
TABLE 254 CYTOVALE, INC.: COMPANY OVERVIEW
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
